# Vibrant Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vibrant-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.vibrantx.com/
- Latest round: Series A (Aug 25, 2025)
- Investors on record: 4

## About

Based in the US, and established in 2019, Xinhua Biopharmaceuticals (Guangzhou) Co., Ltd. trading as Vibrant Therapeutics, is a biopharmaceutical company that focuses on R&D of macromolecular drugs taking the technology of artificial intelligence (AI). The company's founder is Larry Wang. In January 2026, Vibrant Therapeutics raised USD 61 million in venture funding from Apricot Capital, Pfizer Venture Investments, Bayland Capital, HSG, NLVC. and First Principal Venture Limited.
The company developes an AI-driven macromolecular drug research platform that supports target identification, molecular design and efficacy evaluation. The company also launched VibrantFold, an antibody structure prediction tool. Its drug candidates focus primarily on immuno-oncology applications, particularly for the treatment of solid tumors.
The company generates revenue through collaborative R&D partnerships, licensing of its AI-enabled drug discovery tools and the development of proprietary macromolecular drug candidates for oncology and immune-related diseases.
The company plans to utilize the January 2026 funding for advancement of pipeline, development of proprietary drug design platform, and expansion of team for global development activities.

## Funding rounds

- Series A, Aug 25, 2025 — HSG, Trinity Innovation Fund
- Series A, Aug 25, 2025 — Apricot Capital
- Angel, Dec 22, 2020 — Redhill Capital

## Investors

- Redhill Capital (https://capitalatlas.ai/funds/redhill-capital) — Angel
- HSG (https://capitalatlas.ai/funds/hsg) — Series A
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series A
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A